The Latest from our Resource Centers

prescription-drug
Bipartisan Legislation Introduced by Senators Grassley and Klobuchar

Prescription Drug: Legislation

Bipartisan Legislation Introduced by Senators Grassley and Klobuchar

March 19, 2019

The bill would temporarily allow drugs to be imported from certain other countries if facing a shortage or lack of competition.

POST

prescription-drug
Members Send Letter to HHS Opposing Changes to Protected Classes

Prescription Drug: Other

Members Send Letter to HHS Opposing Changes to Protected Classes

March 15, 2019

On March 13, 2019, more than 70 members joined Representatives Barbara Lee (D-CA) and Will Hurd (R-TX) in sending a letter to Secretary and of Health and Human Services Alex Azar expressing opposition to the CMS proposed rule changing the six protected classes of drugs in Medicare Part D.

POST

prescription-drug

Prescription Drug: Other

CMS Updates Drug Spending Dashboards

March 15, 2019

CMS updated its drug spending dashboards with data for 2017.

POST

prescription-drug
Prescription Drug Legislation Considered

Prescription Drug: Legislation

Prescription Drug Legislation Considered

March 15, 2019

House E&C Health Subcommittee holds legislative hearing to examine seven bills related to lowering the cost of prescription drugs.

POST

prescription-drug
President’s FY 2020 Budget Includes Drug Proposals

Prescription Drug: Original Analysis

President’s FY 2020 Budget Includes Drug Proposals

March 13, 2019

The White House FY 2020 budget proposal

POST

prescription-drug

Prescription Drug: Legislation

Accelerated Drug Approval for Prescription Therapies (ADAPT) Act

March 11, 2019

On March 6, 2019, Senator Mike Braun (R-IN) introduced the Accelerated Drug Approval for Prescription Therapies (ADAPT) Act (S. 658), which would create an expedited drug approval process at FDA specifically for drugs that are currently approved for sale in developed countries.

EXTERNAL LINK

prescription-drug

Prescription Drug: Legislation

Drug Price Transparency (DPT) Act

March 11, 2019

On March 6, 2019, Senator Mike Braun (R-IN) introduced the Drug Price Transparency (DPT) Act (S. 657), which would extend the idea of the HHS OIG PBM rebate rule to the commercial insurance market and prohibit PBMs from receiving any rebates or reductions in price from drug manufacturers.

EXTERNAL LINK

prescription-drug

Prescription Drug: Issue Primers

Trump Administration Drug Pricing Blueprint Policies and Proposals Tracker

March 08, 2019

McDermottPlus’ American Patients First: The Trump Administration Blueprint to Lower Drug Prices and Reduce Out-of-Pocket Costs Policies and Proposals Tracker

POST

prescription-drug

Prescription Drug: Legislation

The Medicare Negotiation and Competitive Licensing Act (S. 377)

February 07, 2019

POST

prescription-drug

Prescription Drug: Legislation

The Medicare Negotiation and Competitive Licensing Act (H.R. 1046)

February 07, 2019

POST

prescription-drug

Prescription Drug: Pricing , Regulation

Modernizing Part D and Medicare Advantage to Lower Drug Prices and Reduce Out-of-Pocket Expenses

January 25, 2019

EXTERNAL LINK

prescription-drug

Prescription Drug: Legislation

The Medicare Drug Price Negotiation Act (S. 99)

January 10, 2019

POST

prescription-drug

Prescription Drug: Legislation

The Medicare Drug Price Negotiation Act (H.R. 448)

January 10, 2019

POST

prescription-drug

Prescription Drug: Legislation

Empowering Medicare Seniors to Negotiate Drug Prices Act of 2019 (S. 62)

January 09, 2019

POST

prescription-drug

Prescription Drug: Legislation

Medicare Prescription Drug Price Negotiation Act of 2019

January 08, 2019

POST

prescription-drug

Prescription Drug: Original Analysis

Court Issues Permanent Injunction Blocking Medicare 340B Payment Cuts

December 27, 2018

POST

prescription-drug

Prescription Drug: Regulation

Ceiling Price Effective Date

November 30, 2018

EXTERNAL LINK

prescription-drug

Prescription Drug: Original Analysis

Administration Offers Up New Proposals to Cut Drug Costs

November 26, 2018

POST

prescription-drug

Prescription Drug: Original Analysis

CMS Requests Comment on Potential IPI Model for Part B Drugs

October 25, 2018

POST

prescription-drug

Prescription Drug: Pricing , Regulation

ANPRM IPI Model for Medicare Part B Drugs

October 25, 2018

EXTERNAL LINK

prescription-drug

Prescription Drug: Pricing , Regulation

Regulation to Require Drug Pricing Transparency

October 18, 2018

EXTERNAL LINK

prescription-drug

Prescription Drug: Original Analysis

White House Builds Momentum for Drug Price Controls

May 21, 2018

POST

prescription-drug

Prescription Drug: Guidance

American Patients First Blueprint

May 01, 2018

EXTERNAL LINK

Load more
beakernav X1E2BFA62-BFCE-43C1-B777-27E3E5216018medical bagoriginal analysis +external linkpdf downloadstethoscope